Daliresp (Roflumilast) – Patient-Friendly Guide (UK)

Daliresp is the brand name of roflumilast, a medicine used to treat certain long-term lung conditions. This guide explains how it works, how it’s usually taken, what to watch for, and practical tips to help you use it safely and effectively in the United Kingdom.

Note: Always follow the specific instructions given by your healthcare professional and the information in the patient leaflet supplied with your medicine.

Quick product overview

What Daliresp is used for

Daliresp (roflumilast) is used in the management of COPD, a long-term condition that makes it difficult to breathe due to airflow limitation. It is particularly intended for people with:

• Severe COPD and
• Chronic bronchitis (productive cough with mucus)
• And who have had exacerbations (flare-ups) despite appropriate inhaled treatments

Daliresp is designed to help reduce the number of COPD flare-ups. It is not a fast-acting “rescue” medicine for sudden breathlessness.

How Daliresp works (mechanism of action)

Roflumilast belongs to a group of medicines called phosphodiesterase-4 (PDE4) inhibitors.

PDE4 is involved in inflammation pathways in the lungs. By inhibiting PDE4, roflumilast helps to:

• Reduce inflammatory signalling in the airways
• Decrease mucus-related inflammation that can worsen COPD symptoms
• Lower the risk of COPD exacerbations in people with chronic bronchitis

Over time, this can contribute to improved disease control and fewer flare-ups.

When it starts working (timing and expectations)

Daliresp is typically taken once daily. Its benefit is usually measured over weeks to months, rather than minutes or hours.

• Early period: some people notice side effects (such as diarrhoea or nausea) shortly after starting.
• Ongoing use: reduction in exacerbation risk is expected with regular use.
• If you feel better quickly: continue taking it as directed to maintain control.
• If symptoms worsen: seek advice promptly, especially if you have sudden deterioration in breathing.

Dosing information (typical UK use)

The exact dose for you may depend on your age, tolerability, other medicines, and COPD severity. Many patients are started with a lower dose to improve stomach tolerance, then adjusted.

Typical dosing (general guidance):

• Usually once daily.
• Initial dose: some patients start with a lower strength (often 250 mcg) before moving to 500 mcg daily, as advised.
• Maintenance dose: commonly 500 mcg once daily for long-term use.

Take your tablet at the same time each day to help you remember. If you miss a dose, follow the instructions in your leaflet or ask your pharmacist for personalised guidance.

How to take Daliresp (practical use tips)

• Swallow whole with water; do not crush or break unless your clinician/pharmacist advises otherwise.
• Consistency helps: taking it at a routine time improves adherence.
• Manage stomach effects: if diarrhoea or nausea occurs, tell your healthcare professional. Dose adjustment or supportive measures may be considered.
• Monitor weight: weigh yourself regularly (for example, weekly) if you’re at risk of weight loss.
• Keep track of COPD symptoms: note flare-ups, new cough/mucus changes, fever, or breathlessness so you can discuss trends.

If you have severe side effects, do not stop suddenly without medical advice—seek guidance promptly.

Food interactions and dietary considerations

Food and drinks: Roflumilast can be taken with or without food for most people. However, because gastrointestinal side effects are common, some patients find it easier to take the tablet with a meal or after food to reduce nausea or abdominal discomfort.

• Diarrhoea: drink fluids to avoid dehydration.
• Weight loss risk: maintain adequate calorie intake and discuss any unintended weight loss early.

If you have conditions affecting digestion (such as inflammatory bowel disease), ask your clinician about suitability.

Alcohol and medicine interactions

Alcohol

There is no specific “hard” interaction listed for alcohol in many patient-facing materials, but alcohol may:

• Worsen gastrointestinal upset (nausea, diarrhoea, stomach pain)
• Increase dizziness or tiredness in some people

For safety, consider avoiding or limiting alcohol—especially during the first weeks of treatment—until you know how Daliresp affects you.

Interactions with other medicines

Roflumilast is metabolised in the body (primarily via liver enzymes). Certain medicines can change its levels, either increasing side effects or reducing effectiveness.

Medicines that may be relevant to discuss with your healthcare professional:

• Strong enzyme inducers (may lower roflumilast levels), e.g. certain seizure medicines or some tuberculosis treatments
• Other medicines affecting liver enzyme pathways
• Medicines that cause similar gastrointestinal effects (may increase the likelihood of diarrhoea/nausea)
• Medicines used for COPD (typically inhaled therapies may be continued, but review your whole regimen)

Always provide a full list of current medicines, including over-the-counter products and herbal remedies, to help avoid interactions.

Pharmacokinetics (how the body handles roflumilast)

“Pharmacokinetics” describes absorption, metabolism, distribution, and elimination. The following overview is written in patient-friendly terms.

• Absorption: after oral dosing, roflumilast is absorbed and reaches peak levels within hours.
• Metabolism: roflumilast is extensively metabolised in the liver to active metabolites.
• Half-life: the active components persist long enough to allow once-daily dosing.
• Elimination: metabolites are removed mainly through kidney and/or bile routes (as described in prescribing information).

Because liver metabolism is involved, caution may be required if you have liver problems. Your prescriber should assess suitability and monitor as needed.

Safety profile and side effects

Most medicines have side effects. With Daliresp, the most common are those affecting the gastrointestinal tract and weight. Many people tolerate the medicine better after the initial adjustment period.

Common side effects

• Diarrhoea
• Nausea
• Abdominal pain or discomfort
• Headache
• Insomnia or sleep disturbance
• Reduced appetite
• Weight loss (important to monitor)

Less common but serious warning signs

Seek urgent medical advice if you experience:

• Severe diarrhoea that leads to dehydration or weakness
• Unintended significant weight loss or signs of malnutrition
• Severe mood changes, agitation, or suicidal thoughts

If you have a history of psychiatric illness, discuss this with your clinician before starting.

Who should take extra care?

• People prone to weight loss or underweight
• Those with a history of depression or mental health conditions
• People with liver impairment
• People experiencing persistent gastrointestinal symptoms

Practical “during treatment” checklist

• Track your weight (weekly at the same time of day).
• Watch for diarrhoea: drink fluids; contact your healthcare team if it persists or is severe.
• Sleep changes: if insomnia occurs, discuss strategies (timing, sleep hygiene) with your clinician.
• Mood monitoring: inform your healthcare team promptly about depression, anxiety, or unusual behaviour.
• Keep inhaler routine: Daliresp is an add-on in many regimens—do not stop your inhaled medicines unless advised.
• Know your flare-up plan: have clear guidance on when to use rescue inhalers and when to seek urgent help.

Alternative options for COPD (discuss with your clinician)

COPD treatment is individual. Daliresp is one option for reducing exacerbations in selected patients. Depending on your symptoms, lung function, and exacerbation history, healthcare professionals may consider:

• Inhaled therapies such as:
  • Long-acting bronchodilators (LAMA and LABA)
  • Inhaled corticosteroids (ICS) in combination for specific cases
• Vaccinations (flu and pneumococcal) to reduce infection-triggered exacerbations
• Smoking cessation support (if relevant)—often the most effective step for slowing disease progression
• Pulmonary rehabilitation to improve breathlessness and activity tolerance
• Other exacerbation-reducing medicines in appropriate cases (your clinician will advise based on your profile)

Choice of therapy depends on lung function, symptom pattern, exacerbation frequency, comorbidities, and tolerability. Never swap medicines without guidance.

UK market and legal context (high-level overview)

In the United Kingdom, medicines such as Daliresp are regulated and authorised for use by the UK medicines framework. Availability may vary by product strength, prescribing arrangements, and supply routes.

As a patient, you can usually access medicines through:

• NHS services (for eligible patients)
• Private healthcare routes
• Pharmacy supply where permitted and consistent with UK regulations

Guidance and usage recommendations for COPD in the UK are often influenced by bodies such as National Institute for Health and Care Excellence (NICE) and clinical respiratory guidance. Clinicians also consider safety warnings and updates issued by medicines regulators.

Recent guidance and monitoring themes (UK)

COPD management guidance in the UK commonly emphasises:

• Optimising inhaled therapy and ensuring correct inhaler technique
• Reducing exacerbations through targeted add-on treatments in suitable patients
• Vaccination and infection prevention
• Smoking cessation and lifestyle interventions
• Regular review of symptom burden, exacerbation history, and side effects
• Monitoring for adverse effects such as weight change with medicines known to affect weight

For roflumilast specifically, clinicians typically focus on tolerability (gastrointestinal effects), weight monitoring, and mental health screening where relevant.

Delivery and availability in the UK

Online pharmacies in the UK may provide delivery of medicines depending on the product category, stock availability, and local regulatory requirements. Availability can be influenced by:

• Current stock levels and manufacturer supply
• Strength or pack size requested
• Peak demand periods (for example, seasonal COPD exacerbations)

When ordering, ensure you select the correct strength and quantity and provide delivery details accurately. Delivery timelines vary by supplier and location; your pharmacy should display estimated delivery times at checkout.

Tip: If you are taking Daliresp long-term, consider ordering early to avoid running out.

Frequently Asked Questions (FAQ)

1) Is Daliresp used for sudden breathlessness?

No. Daliresp is intended to help reduce COPD exacerbations over time. It is not a rapid-relief rescue medicine. For sudden symptoms, follow your COPD action plan and use your fast-acting inhaler as instructed.

2) How long do I need to take Daliresp?

Many patients take it as long-term maintenance therapy to reduce exacerbations in appropriate COPD. The exact duration should be reviewed regularly with your clinician, particularly if symptoms stabilise or side effects become problematic.

3) What should I do if I get diarrhoea or nausea after starting?

These are common early side effects. Keep hydrated, take the tablet consistently (many people find taking it with food helps), and contact your healthcare professional if symptoms are severe, persistent, or lead to dehydration. Dose adjustments may be considered.

4) Will Daliresp make me lose weight?

Weight loss can occur. It’s not guaranteed for everyone, but it’s important enough that clinicians often monitor body weight. Tell your healthcare professional if you notice unintended weight loss or reduced appetite.

5) Can I take Daliresp with food?

Often yes. Taking it with food may improve stomach comfort for some people. If your doctor/pharmacist advised a specific approach, follow that advice.

6) Can I drink alcohol while taking Daliresp?

It’s best to limit alcohol, especially early in treatment, because it may worsen gastrointestinal symptoms and general wellbeing. If you plan to drink, discuss your situation with your pharmacist or clinician.

7) Are there interactions with my inhalers?

Inhaled COPD medicines are commonly used alongside roflumilast, but your full treatment plan should be reviewed. Always tell your healthcare team about all medicines you use, including inhalers, tablets, and herbal products.

8) Who should not take Daliresp?

People with certain conditions may need extra caution, such as those with significant liver impairment or who have a history of psychiatric illness. Your clinician will assess suitability based on your medical history and current medicines.

9) What if I miss a dose?

If you miss a dose, follow the instructions in the patient leaflet or ask your pharmacist. In general, don’t take a double dose to make up for a missed tablet.

10) When should I seek urgent help?

Seek urgent medical advice for severe or persistent diarrhoea with dehydration, severe abdominal pain, rapid or significant weight loss, or concerning mood changes.

Summary

Daliresp (roflumilast) is a once-daily tablet used in selected people with severe COPD and chronic bronchitis to help reduce exacerbations. It works by inhibiting PDE4, reducing inflammatory activity in the airways. Because side effects—especially diarrhoea, nausea, and weight loss— can occur, it’s important to monitor your symptoms, maintain hydration, and keep an eye on body weight.

If you have questions about suitability, dosing, interactions, or side effects, speak to a healthcare professional or your pharmacist.